TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Composite Clinician Severity Rating (CSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation dose during VCUG procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinically important changes in safety assessment results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resolution of ectopic pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum hCG levels below laboratory immunoassay detection <15 IU/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC GIR 360-720 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal mucosa color difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score on Moving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapy Adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: absence of postoperative morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Weight of drug suspension delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Dependence Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Opiate Withdrawal Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Short Form (36) Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: successful rate of first intravascular access attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Growth of Gleason grade 3 prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Subjects on Lacosamide (LCM) Monotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of Lacosamide (LCM) Monotherapy Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of all stressful events
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Failure Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Hopkins Symptom Checklist (HSCL-25)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: World Health Organization Quality of Life assessment (WHOQOL-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: histological tissue evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General cognitive index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in 24 Hour Creatinine Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: acceptable side effects
Endpoint domain: Adverse events/effects
Primary endpoint: regional left ventricle 99mTc-DPD uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Net oxygen cost (OC, ml/kg/m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Net heart rate (HR, beats/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Net minute ventilation (VE, L/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Net respiratory exchange ratio (RER, no unit)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: iron deficiency symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in brain activity (cerebral blood flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: Glycocalyx thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Failures
Endpoint domain: Adverse events/effects
Primary endpoint: Drainage Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosing Compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants with adverse events related to study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative of adverse events related to study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of adverse events related to study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Mean BG After First Day of Hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence or absence of orthostatic hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients reaching therapeutic goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained biochemical responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on measure of parent knowledge regarding traumatic stress and coping assistance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Growth parameters (weight and height)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overdose reversals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise calf muscle perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise calf muscle energetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of advanced AMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cataract surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Eyes With > Grade 2 Slit Lamp Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Crizotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D) of Crizotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Objective Response (OR)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rasmussen scores change after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rasmunssen radiological evaluation scores change after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The quality of reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of diagnosis of Acute mesenteric ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in JAK2 V617F allele frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in the 6 minute walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of diabetes subjects achieving glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of pre-diabetes achieving euglycemic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of subjects achieving Complete Control of CINV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gamma-glutamyltransferase (GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximum hypnotic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSQI Change
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Clinical and pathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain after orbital decompression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Human Anti-chimeric Antibody (HACA)
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal respiratory distress syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants reporting Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants reporting Treatment Emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants reporting AEs of Special interests (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in glomerular renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ipsilateral breast tumour recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Body pressure mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choroidal and optic nerve head blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum concentration of irisin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in grams of urinary leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of patient survival
Endpoint domain: Mortality/survival
Primary endpoint: Rate of primary non-function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent change in ACC GABA and Glutamate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: remission (MADRS ≤9) at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Routine blood test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Latency to Persistent Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of insulin daily doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference of glucose concentrations (fasting and post-prandial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Absolute band power in every frequency band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in EMG Signal of Tibialis Anterior Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in RBANS Composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Neuraxial Analgesic Drug Consumption Per Hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular salvage rates
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline Hamilton Rating Scale for Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose (MTD) of ipilimumab
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of nivolumab
Endpoint domain: Adverse events/effects
Primary endpoint: cognitive function change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: treatment change assessed by serum levels of energy metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting plasma HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of immune response (antibodies)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite score of cognitive tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction of mutans streptococci and/or lactobacilli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of Recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: percentage of IFN1 producing pDCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of deaths related to study treatment
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of grade >= III acute GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital treatment costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Daily Total Dose of Oral Morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of numeration (cfu per ml) of GNB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Functional magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of glucose-induced changes in peripheral ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of Fingerstick Blood Glucose Results within specified ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total VSC readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients developing severe infection
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in regulators of lipid turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to next treatment (TNT)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of occurrence of dural puncture
Endpoint domain: Adverse events/effects
Primary endpoint: change in help seeking behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in aphasia level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence of Intra-fragmentary mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intratumoral T-cell numbers and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in myeloid cell numbers and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RNA gene expression in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak values of troponin and CKMB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Without Contamination of Contact Lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unfavourable neurological outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Severe disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects Achieving PedACR30 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Mitral Regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hypoxia Inducible Factor 1 alpha levels in circulating leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spect signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spect noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Area under the curve of CA 125
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence and severity of hypersensitivity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of side effects as rated with the UKU scale
Endpoint domain: Adverse events/effects
Primary endpoint: Successful Initial IV Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to recovery from anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of recurrent adhesions after adhesiolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of complications after adhesiolysis
Endpoint domain: Adverse events/effects
Primary endpoint: Pain-free walking distance (PFWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital rate of permanent colostomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hospital rate of local recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall level of DNA methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Overdue Women Returning for Screening Mammography
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Distribution volume (VT) of NOP receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number and percentage of subjects with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and percentage of subjects with serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and percentage of subjects with dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of common warts cleared
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24 hour urine albumin to creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Interleukin-1/Total Protein (Skin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Transcutaneous Tissue Oxygen (TcPO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Skin Moisture (Epidermal and Subepidermal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Skin Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Skin Interface Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in dietary diversity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum lipid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: density of the deep capillary plexus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on Social Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Fixed and variable costs resulting from Total Knee Arthroplasty at 30 days post-op
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fixed and variable costs resulting from Total Knee Arthroplasty at 90 days post-op
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quantitative Strain Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative Color endoscopy ultrasound elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicities Including Grades 1 to 4
Endpoint domain: Adverse events/effects
Primary endpoint: Documented Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression to a Higher-grade Dysplasia or Carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Flow-mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Nitroglycerin-mediated Vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Endothelial Progenitor Cells (EPCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Survival at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Percentage Change in Total Lesion Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrophy of the myofibers of the human diaphragm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Post-engraftment maturation of NET formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Neonatal Omphalitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of Neonatal Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Biologic Activity Endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Oxygen Level Dependent in ventral striatum and amygdala
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes